Preferential Energy- and Potential-Dependent Accumulation of Cisplatin–Gutathione Complexes in Human Cancer Cell Lines (GLC4 and K562): A Likely Role of Mitochondria
- 79 Downloads
cis-Diamminedichloroplatinum(II) (CDDP) is an important chemotherapeutic agent used in the treatment of a wide variety of solid tumors. We have recently shown that aquated forms of cisplatin (aqua-Pt) rapidly accumulate in K562 and GLC4 cultured cells, in comparison to CDDP. Thus, when cells are incubated with aquated forms of cisplatin a gradient of concentration is observed after a short time, approximately 40 min, with an intracellular concentration of aqua-Pt of 20–30 times higher than that of extracellular aqua-Pt. The same gradient of concentration is observed when cells are incubated with CDDP but it takes a longer time, i.e., about 24 h. Therefore, the question arises as to the identity of the intracellular sites of accumulation of aqua-Pt. Using several agents to modulate membrane potential, acidic compartment pH and/or ATP level, we obtained evidence that aqua-Pt may accumulate rapidly inside mitochondria as this accumulation is energy- and membrane-potential-dependent. However, aqua-Pt complexes are not characterized by a delocalized charge and a lipophilic character that would permit their movement through the inner membrane. Therefore, it is suggested that intracellular aqua-Pt reacts rapidly with glutathione with the resultant complex being transported inside the mitochondria via one of the known glutathione transporters, i.e., dicarboxylate and/or 2-oxoglutarate transporters present in the inner membrane.
KeywordsCisplatin Mitochondria Glutathione Accumulation
cis-diammine-dichloro-platinum(II) or cisplatin
once deprotonated glutathione
Unable to display preview. Download preview PDF.
- Basolo F, and Pearson R G (1967) In Mechanisms of Inorganic Reactions, Wiley, New York, pp 351–453Google Scholar
- Chen Z, and Lash L H (1998) J Pharm Exp Ther 285:608–618Google Scholar
- Dwyer P J O, Stevenson J P, and Johnson S W (1999) In Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert, B, ed), VHCA, Basel, Switzerland, pp 31–69Google Scholar
- Lieberthal W, Triaca V, and Levine J (1996) Am J Physiol (Renal Fluid Electrolyte Physiol) 270:F700–F708Google Scholar
- Lim M C, and Martin B (1976) J Inorg Nucl Chem 38:1191–1914Google Scholar
- Roberts J J, Knox R J, Friedlos F, et al (1986) In Biochemical Mechanisms of Platinum Antitumor Drugs (Mc Brien, C H, and Slater, T F, eds), IRL Press, Oxford, pp 29–64 Google Scholar